CD271 is a negative prognostic factor and essential for cell proliferation in lung squamous cell carcinoma

Mochizuki, Mai; Nakamura, Mao; Sibuya, Rie; Okazaki, Taro; Abe, Jiro; Nakagawa, Takayuki; Takahashi, Satoshi; Yamazaki, Tomoko; Imai, Takayuki; Takano, Atsushi; Ito, Hiroyuki; Yokose, Tomoyuki; Miyagi, Yohei; Daigo, Yataro; Sato, Iwao; Satoh, Kennichi; Sugamura, Kazuo; Yamaguchi, Kazunori; Tamai, Keiichi

doi:10.1038/s41374-019-0246-5

Cited by 12 publications

(31 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, cell cycle, pentose and glucuronate interconversions, ascorbate and aldarate metabolism, and metabolic pathways were among the top 15 enriched pathways (Figure 1E, left panel and Supplementary Table S2). These findings are consistent with our knowledge about cancer cells that their cell proliferation is much more rapid than in normal cells (33)(34)(35), and these processes are material and energy dependent. On the contrary, genes in cell adhesion, extracellular matrix organization, immune response, inflammatory response, chemotaxis, and chemokine-mediated signaling pathwayrelated biological processes were suppressed (Figure 1D, right panel and Supplementary Table S2).…”

Section: Resultssupporting

confidence: 92%

A Systematic Analysis Identifies Key Regulators Involved in Cell Proliferation and Potential Drugs for the Treatment of Human Lung Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is one of the most common and malignant cancer types. Abnormal cell proliferation, exemplified by cell cycle and cell division dysregulation, is one of the most prominent hallmarks of cancer and is responsible for recurrence, metastasis, and resistance to cancer therapy. However, LUAD-specific gene regulation and clinical significance remain obscure. Here, by using both tissues and cells from LUAD and normal lung samples, 434 increased and 828 decreased genes of biological significance were detected, including 127 cell cycle-associated genes (95 increased and 32 decreased), 66 cell division-associated genes (56 increased and 10 decreased), and 81 cell proliferation-associated genes (34 increased and 47 decreased). Among them, 12 increased genes (TPX2, CENPF, BUB1, PLK1, KIF2C, AURKB, CDKN3, BUB1B, HMGA2, CDK1, ASPM, and CKS1B) and 2 decreased genes (TACC1 and MYH10) were associated with all the three above processes. Importantly, 2 (CDKN3 and CKS1B) out of the 11 increased genes (except HMGA2) are previously uncharacterized ones in LUAD and can potentially be prognostic markers. Moreover, PLK1 could be a promising therapeutic target for LUAD. Besides, protein–protein interaction network analysis showed that CDK1 and CDC20 were the hub genes, which might play crucial roles in cell proliferation of LUAD. Furthermore, transcriptional regulatory network analysis suggested that the transcription factor E2F1 could be a key regulator in controlling cell proliferation of LUAD via expression modulation of most cell cycle-, cell division-, and cell proliferation-related DEGs. Finally, trichostatin A, hycanthone, vorinostat, and mebeverine were identified as four potential therapeutic agents for LUAD. This work revealed key regulators contributing to cell proliferation in human LUAD and identified four potential therapeutic agents for treatment strategy.

show abstract

Section: Resultssupporting

confidence: 92%

A Systematic Analysis Identifies Key Regulators Involved in Cell Proliferation and Potential Drugs for the Treatment of Human Lung Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition, the expression of CD271 was associated with increased migration/invasion and metastasis of head and neck cancer, hypopharyngeal cancer, and oral squamous cell carcinoma [ 115 , 116 , 117 ] and was associated with poor prognosis of LSCC [ 118 ] and urothelial carcinoma (TCGA, human protein atlas, Figure S7b ). Strikingly, the tumor formation of engrafted hypopharyngeal cancer and melanoma cells was blocked by a humanized anti-CD271 antibody [ 119 ].…”

Section: Signaling Of Cd271 In Melanoma and Other Cancer Typesmentioning

confidence: 99%

Decoding the Role of CD271 in Melanoma

Vidal

Redmer

2020

Cancers

View full text Add to dashboard Cite

The evolution of melanoma, the most aggressive type of skin cancer, is triggered by driver mutations that are acquired in the coding regions of particularly BRAF (rat fibrosarcoma serine/threonine kinase, isoform B) or NRAS (neuroblastoma-type ras sarcoma virus) in melanocytes. Although driver mutations strongly determine tumor progression, additional factors are likely required and prerequisite for melanoma formation. Melanocytes are formed during vertebrate development in a well-controlled differentiation process of multipotent neural crest stem cells (NCSCs). However, mechanisms determining the properties of melanocytes and melanoma cells are still not well understood. The nerve growth factor receptor CD271 is likewise expressed in melanocytes, melanoma cells and NCSCs and programs the maintenance of a stem-like and migratory phenotype via a comprehensive network of associated genes. Moreover, CD271 regulates phenotype switching, a process that enables the rapid and reversible conversion of proliferative into invasive or non-stem-like states into stem-like states by yet largely unknown mechanisms. Here, we summarize current findings about CD271-associated mechanisms in melanoma cells and illustrate the role of CD271 for melanoma cell migration and metastasis, phenotype-switching, resistance to therapeutic interventions, and the maintenance of an NCSC-like state.

show abstract

“…Besides, proteins, such as tripartite motif-containing protein59 (TRIM59), minichromosome maintenance protein 2 (MCM2) and CD271 were highly expressed, while the expression of interferon-induced proteins with tetratricopeptide repeats 2 (IFIT2) was decreased in LUSCC cell lines or tissues [12]. The overall survival (OS) of patients with high TRIM59, MCM2, CD271 expression or low IFIT2 expression were significantly better than the opposite group [12][13][14][15][16]. However, the sensitivity and specificity was not satisfactory using one biomarker.…”

Section: Ivyspringmentioning

confidence: 99%

Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma

Fang¹,

Liu²,

Weng³

et al. 2020

Int. J. Med. Sci.

View full text Add to dashboard Cite

Lung squamous cell carcinoma (LUSCC), as the major type of lung cancer, has high morbidity and mortality rates. The prognostic markers for LUSCC are much fewer than lung adenocarcinoma. Besides, protein biomarkers have advantages of economy, accuracy and stability. The aim of this study was to construct a protein prognostic model for LUSCC. The protein expression data of LUSCC were downloaded from The Cancer Protein Atlas (TCPA) database. Clinical data of LUSCC patients were downloaded from The Cancer Genome Atlas (TCGA) database. A total of 237 proteins were identified from 325 cases of LUSCC patients based on the TCPA and TCGA database. According to Kaplan-Meier survival analysis, univariate and multivariate Cox analysis, a prognostic prediction model was established which was consisted of 6 proteins (CHK1_pS345, CHK2, IRS1, PAXILLIN, BRCA2 and BRAF_pS445). After calculating the risk values of each patient according to the coefficient of each protein in the risk model, the LUSCC patients were divided into high risk group and low risk group. The survival analysis demonstrated that there was significant difference between these two groups (p= 4.877e−05). The area under the curve (AUC) value of the receiver operating characteristic (ROC) curve was 0.699, which suggesting that the prognostic risk model could effectively predict the survival of LUSCC patients. Univariate and multivariate analysis indicated that this prognostic model could be used as independent prognosis factors for LUSCC patients. Proteins co-expression analysis showed that there were 21 proteins co-expressed with the proteins in the risk model. In conclusion, our study constructed a protein prognostic model, which could effectively predict the prognosis of LUSCC patients.

show abstract

CD271 is a negative prognostic factor and essential for cell proliferation in lung squamous cell carcinoma

Cited by 12 publications

References 22 publications

A Systematic Analysis Identifies Key Regulators Involved in Cell Proliferation and Potential Drugs for the Treatment of Human Lung Adenocarcinoma

A Systematic Analysis Identifies Key Regulators Involved in Cell Proliferation and Potential Drugs for the Treatment of Human Lung Adenocarcinoma

Decoding the Role of CD271 in Melanoma

Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma

Contact Info

Product

Resources

About